- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05981430
Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae (FMT)
Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae: a Double Blind Randomized Controlled Trial
The emergence of multidrug-resistant organisms (MDROs) has become one of the major threats to the healthcare system in Hong Kong in recent years. The situation is particularly worrisome for carbapenem-resistant Enterobacteriaceae (CRE). Taking Queen Mary Hospital as an example, the number of CRE cases has surged from 24 in year 2014 to 625 in year 2021. The case burden in Hong Kong is therefore substantial when all 43 public hospitals and institutions in Hong Kong are considered. With the widespread use of broad-spectrum antibiotics and active case screening, the number of CRE cases is expected to further increase in an exponential manner.
Given that colonization with MDROs is due to gut dysbiosis from antibiotic use, a normal intestinal microbiota is apparently crucial in protecting hosts from colonization with MDROs including CRE. Fecal microbiota transplantation (FMT), which involves the infusion of stool from a healthy donor to the gastrointestinal (GI) tract of a recipient, has gained popularity in recent years to restore colonic microbial diversity in various diseases associated with gut dysbiosis, e.g. Clostridium difficile (CD) infection, ulcerative colitis and even metabolic diseases. The investigators aim to conduct a double-blind randomized controlled trial to evaluate the benefit of FMT via lower GI delivery (enema) on CRE clearance.
Study Overview
Status
Intervention / Treatment
Detailed Description
CRE colonization is associated with a 16.5% risk of infection with a 10% mortality rate. CRE also poses a tremendous strain on the healthcare cost as well as the medical/nursing manpower. The hospital stay is lengthened by two-fold for CRE-infected cases compared with non-infected cases. CRE carriers frequently have to stay in acute hospitals for extended periods of time after settling their acute illnesses, both because of the logistic infeasibility of them being transferred to rehabilitation units or nursing homes, which are devoid of isolation rooms.
Proactive measures have been implemented in hospitals worldwide to prevent the spread of MDROs, especially to vulnerable individuals. Such measures usually include surveillance culture, contact tracing, isolation of carriers and environmental disinfection. Nevertheless, isolation facilities are not always readily available, particularly in resource-limited regions. In addition, contact isolation may result in various adverse effects on the mental well-being of isolated patients, such as depression, anxiety and anger. Time spent with patients in isolation by healthcare workers is less, with a negative effect on patient safety with an eight-fold increase in the risk of adverse events due to supportive care failure.
There has been a growing interest in extending FMT for the decolonization of CRE. However, most of the studies are limited to case reports or case series with small sample sizes (ranging from 10 to 39 patients) as shown by a recent systematic review. The pooled rate of CRE decolonization is promising at 62.1%. However, a randomized controlled trial (RCT) remains the most optimal study design to investigate the true beneficial effect of FMT on CRE decolonization. FMT via enema route has several advantages over upper GI delivery or colonoscopy. First, the administration of fecal suspension via a feeding tube may not be acceptable to some patients. Second, colonoscopy carries complications of gut perforation, aspiration, and cardiopulmonary suppression from the use of sedatives, in particular among frail and elder patients.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ka Shing Cheung
- Phone Number: 22554769
- Email: cks634@hku.hk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All adult patients aged 18 or above admitted to the medical ward of Queen Mary Hospital, the teaching hospital of the University of Hong Kong
- Rectal swabs or stool specimens showing the presence of CRE
- Positive CRE specimen within one week of commencement
Exclusion Criteria:
- Pregnancy
- Severe immunodeficiency (e.g. advanced human immunodeficiency virus infection (CD4 lymphocyte count ≤200/mm3), myelosuppressive chemotherapy)
- Significant neutropenia (absolute neutrophil count ≤1.0 x 109/L)
- Recent antibiotic use within 30 days prior to consent
- Contraindications for retention enema (intestinal obstruction, ileus and gut perforation).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Fecal microbiota transplant
This group's subject will receive an infusion of 125mL fecal suspension via enema.
|
Active comparator will receive infusion of 125mL fecal suspension via enema
|
Placebo Comparator: Sham fecal microbiota transplant
This group's subject will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food colouring 204 (Americolorcorp) as a sham procedure.
|
Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CRE clearance rate
Time Frame: 1 month post-FMT
|
CRE clearance rate via enema
|
1 month post-FMT
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CRE clearance rate
Time Frame: 1 week, 2 week, 3 month, 6 month and 12 month post-FMT
|
CRE clearance rate post-FMT
|
1 week, 2 week, 3 month, 6 month and 12 month post-FMT
|
All-cause mortality
Time Frame: 1 month, 3 month, 6 month and 12 month post-FMT
|
All-cause mortality post-FMT
|
1 month, 3 month, 6 month and 12 month post-FMT
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ka Shing Cheung, The University of Hong Kong
Publications and helpful links
General Publications
- Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017 Sep;46(5):479-493. doi: 10.1111/apt.14201. Epub 2017 Jul 14.
- Backman C, Taylor G, Sales A, Marck PB. An integrative review of infection prevention and control programs for multidrug-resistant organisms in acute care hospitals: a socio-ecological perspective. Am J Infect Control. 2011 Jun;39(5):368-378. doi: 10.1016/j.ajic.2010.07.017. Epub 2011 Mar 23.
- Macareno-Castro J, Solano-Salazar A, Dong LT, Mohiuddin M, Espinoza JL. Fecal microbiota transplantation for Carbapenem-Resistant Enterobacteriaceae: A systematic review. J Infect. 2022 Jun;84(6):749-759. doi: 10.1016/j.jinf.2022.04.028. Epub 2022 Apr 21.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UW 19-512
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fecal Microbiota Transplantation
-
Assistance Publique - Hôpitaux de ParisUniversity of Paris 5 - Rene Descartes; Institut National de Recherche pour...WithdrawnFecal Microbiota Transplantation
-
Keimyung University Dongsan Medical CenterRecruitingFecal Microbiota TransplantationKorea, Republic of
-
University Hospital of North NorwayCompletedFecal Microbiota TransplantationNorway
-
MaaT PharmaTerminatedIntensive Care Units | Fecal Microbiota TransplantationFrance
-
Shanghai 10th People's HospitalCompletedSmall Intestinal Bacterial Overgrowth | Fecal Microbiota TransplantationChina
-
Guangzhou First People's HospitalRecruitingFecal Microbiota TransplantationChina
-
Michael ScharlRecruitingCancer | Immunotherapy | Immune Checkpoint Inhibitors | Fecal Microbiota TransplantationSwitzerland
-
MaaT PharmaCompletedFecal Microbiota TransplantationFrance, Italy, Poland
-
Helsinki University Central HospitalUniversity of HelsinkiActive, not recruitingFecal Microbiota Transplantation | Cesarean Section, Affecting Fetus or Newborn | Intestinal MicrobiomeFinland
-
Shanghai 10th People's HospitalRecruiting
Clinical Trials on Fecal microbiota transplant
-
Boston Medical CenterBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts...TerminatedCrohn's DiseaseUnited States
-
Massachusetts General HospitalCompletedClostridium Difficile InfectionUnited States
-
Washington University School of MedicineUniversity of Pennsylvania; Duke University; Centers for Disease Control and... and other collaboratorsCompleted
-
Judith KelsenRecruitingCrohn's Disease | Ulcerative Colitis | Inflammatory Bowel Disease | Clostridium DifficileUnited States
-
University of AlbertaCompletedHepatic EncephalopathyCanada
-
University of AlbertaCompletedCrohn's DiseaseCanada
-
Otto HelveKarolinska Institutet; University of HelsinkiNot yet recruitingMicrobial ColonizationFinland
-
McMaster Children's HospitalThe Hospital for Sick ChildrenRecruitingSmall Intestinal Bacterial OvergrowthCanada
-
University of AlbertaCompletedUlcerative ColitisCanada
-
University of AlbertaUniversity of CalgaryCompletedEnterocolitis Clostridium Difficile RecurrentCanada